- Home
- Companies
- canada manitoba
- tumor targeting
Show results for
Refine by
Tumor Targeting Suppliers Serving Manitoba
40 companies found
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
PROTACs represent a novel strategy for protein degradation that has gained prominence recently. Utilizing bifunctional molecules, PROTACs enable the targeted ubiquitination and subsequent degradation of proteins via the UPS. PROTACs can not only ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional ...
based inSeattle, WASHINGTON (USA)
As the pioneer in the field of spatial biology, NanoString enables scientists across the globe to envision molecular interactions in three dimensions with three different systems, the nCounter Analysis System, the GeoMx Digital Spatial Profiler ...
based inKöln, GERMANY
Singleron Biotechnologies is an innovative molecular diagnostic company dedicated to applying groundbreaking single cell analysis techniques in clinical diagnosis, drug development, and health management. Singleron Biotechnologies is an innovative ...
FocuSCOPE is a high-throughput single cell multi-omics sequencing solution that can detect both genetic variants and transcriptome from the same single cells. Thus, FocuSCOPE® provided a tool to decipher the connection between genotype and ...
based inBasel, SWITZERLAND
Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary ...
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating ...
based inHercules, CALIFORNIA (USA)
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products ...
Antibodies for bioanalysis and drug monitoring of adalimumab and biosimilars. Develop highly selective and sensitive PK and ADA assays for adalimumab (Humira) using our range of ready-made anti-idiotypic antibodies. Highly specific to adalimumab or ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
Glycosylation is a post-translational modification that occurs inside the cell and results in the addition of sugar motifs, “glycans”, to proteins and lipids that are, in most cases, destined for the cell surface. These glycan structures ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
based inBobingen, GERMANY
gKteso develops and manufactures high-precision OEM solutions and subsystems for leading medical devices. With over 30 years of engineering experience, we provide modular radiology and radiotherapy solutions, combining customized development, ...
The RPS Base delivers robotic 6DoF positioning for advanced radiotherapy workflows. It achieves submillimeter correction in pitch, roll, and yaw for precise targeting in stereotactic and image-guided treatments. While being LINAC system agnostic, ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
Target validation is an essential and critical phase of the drug discovery process. This is a crucial step before starting to develop a treatment based on a targeted protein that has been identified to play a role in the disease. The target ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for novel small molecule PD-L1 ...
based inStockholm, SWEDEN
As a leading innovator of precision radiation therapy solutions, Elekta is committed to ensuring that every patient has access to the best cancer care possible. At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical ...
Proven technology for everyone, everywhere. Clinics are required to deliver high-quality, high-volume treatments with increasingly challenging access to capital and resources. Synergy Series is the perfect foundation to establish your pathway to the ...
based inSaint-Herblain Cedex, FRANCE
Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments. The growing medical need and the lack of effective treatments for bone tumors gave rise to Atlanthera in 2011, a drug discovery company focused on bone ...
Specific targeting of tumor bone tissue, Potent antitumor activity, Low systemic toxicity, Prevention of bone ...
based inNiel, BELGIUM
eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platform includes mRNA construct design and optimization, proprietary ...
Therapeutic area: immuno-oncology; Intra-tumoral (IT) ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Prostate cancer is the most common type of cancer (aside from skin) in American men with 13 out of every 100 being diagnosed with the disease during their lifetime.1,2Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is ...
based inMadison, WISCONSIN (USA)
OnLume Surgical is a Madison, WI based medical device company that develops innovative imaging technology designed to advance surgical precision, optimize patient outcomes and reduce morbidity and costs. We have developed a new standard in ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inWichita, KANSAS (USA)
Neotherma Oncology is led by experienced healthcare executives who are working toward the dream of more effective treatments for cancer. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treatment for deep solid ...
NeoTherma Oncology is a clinical stage medical device company developing a proprietary Thermal Treatment (VectRx) system for deep solid tumors. Our technology is based on applying a safe, non-invasive, non-ionizing electromagnetic field to produce ...